Off-target analysis

Learn about how Ark Therapeutics ensured their lead molecule had no significant genomics off-targets.

ARK Therapeutics is concentrated to manufacturing of adenoviral vectors used in gene therapy, and to study and manufacturing of gene therapies. Ark Therapeutics has a gene therapy center and production facility is Kuopio, Finland.


Ark Therapeutics was developing a gene therapy for cancer. They had a lead molecule targeting a specific gene and hoped to find out if there were any unwanted off-target effects.


We developed a combined sequence analysis and gene expression pipeline that categorized genes into targets, secondary targets and off-targets.


The categorization of differentially expressed genes showed how the gene regulation cascade was due to silencing of the primary target, and that the therapy had no significant off-target effects.

Do you want to learn more about this case? Please ask for more from our bioinformatician by using the contact form below!

Try our new Virtual Bioinformatics Core service!

End-of-year offer 2022